Ying L Liu1, Anurag Saraf2, Benjamin Catanese2, Shing M Lee3, Yuan Zhang3, Eileen P Connolly2, Kevin Kalinsky4. 1. Department of Medicine, New York Presbyterian Hospital, Columbia University Medical Center, New York, NY, USA. 2. Department of Radiation Oncology, New York Presbyterian Hospital, Columbia University Medical Center, New York, NY, USA. 3. Department of Biostatistics, Columbia University School of Medicine, New York, NY, USA. 4. Department of Medical Oncology, New York Presbyterian Hospital, Columbia University Medical Center, 161 Fort Washington Ave, Rm 10-1071, New York, NY, 10032, USA. Kk2693@cumc.columbia.edu.
Abstract
BACKGROUND: Obesity may negatively affect survival in breast cancer (BC), but studies are conflicting, and associations may vary by tumor subtypes and race/ethnicity groups. METHODS: In a retrospective review, we identified 273 women with invasive BC administered Adriamycin/Taxane-based neoadjuvant chemotherapy from 2004 to 2016 with body mass index (BMI) data at diagnosis. Obesity was defined as BMI ≥30. Associations between obesity and event-free survival (EFS), using STEEP events, and overall survival (OS), using all-cause mortality, were assessed overall and stratified by tumor subtype [[Hormone Receptor Positive (HR+)/HER2-, HER2+, and Triple-Negative Breast Cancer (TNBC])] in our diverse population. RESULTS: Median follow-up was 32.6 months (range 5.7-137.8 months). Overall, obesity was associated with worse EFS (HR 1.71, 95% CI 1.03-2.84, p = 0.04) and a trend towards worse OS (p = 0.13). In HR+/HER2- disease (n = 135), there was an interaction between obesity and hormonal therapy with respect to OS but not EFS. In those receiving tamoxifen (n = 33), obesity was associated with worse OS (HR 9.27, 95% CI 0.96-89.3, p = 0.05). In those receiving an aromatase inhibitor (n = 89), there was no association between obesity and OS. In TNBC (n = 44), obesity was associated with worse EFS (HR 2.62, 95% CI 1.03-6.66, p = 0.04) and a trend towards worse OS (p = 0.06). In HER2+ disease (n = 94), obesity was associated with a trend towards worse EFS (HR 3.37, 95% CI 0.97-11.72, p = 0.06) but not OS. Race/ethnicity was not associated with survival in any subtype, and there were no interactions with obesity on survival. CONCLUSIONS: Obesity may negatively impact survival, with differences among tumor subtypes.
BACKGROUND:Obesity may negatively affect survival in breast cancer (BC), but studies are conflicting, and associations may vary by tumor subtypes and race/ethnicity groups. METHODS: In a retrospective review, we identified 273 women with invasive BC administered Adriamycin/Taxane-based neoadjuvant chemotherapy from 2004 to 2016 with body mass index (BMI) data at diagnosis. Obesity was defined as BMI ≥30. Associations between obesity and event-free survival (EFS), using STEEP events, and overall survival (OS), using all-cause mortality, were assessed overall and stratified by tumor subtype [[Hormone Receptor Positive (HR+)/HER2-, HER2+, and Triple-Negative Breast Cancer (TNBC])] in our diverse population. RESULTS: Median follow-up was 32.6 months (range 5.7-137.8 months). Overall, obesity was associated with worse EFS (HR 1.71, 95% CI 1.03-2.84, p = 0.04) and a trend towards worse OS (p = 0.13). In HR+/HER2- disease (n = 135), there was an interaction between obesity and hormonal therapy with respect to OS but not EFS. In those receiving tamoxifen (n = 33), obesity was associated with worse OS (HR 9.27, 95% CI 0.96-89.3, p = 0.05). In those receiving an aromatase inhibitor (n = 89), there was no association between obesity and OS. In TNBC (n = 44), obesity was associated with worse EFS (HR 2.62, 95% CI 1.03-6.66, p = 0.04) and a trend towards worse OS (p = 0.06). In HER2+ disease (n = 94), obesity was associated with a trend towards worse EFS (HR 3.37, 95% CI 0.97-11.72, p = 0.06) but not OS. Race/ethnicity was not associated with survival in any subtype, and there were no interactions with obesity on survival. CONCLUSIONS:Obesity may negatively impact survival, with differences among tumor subtypes.
Entities:
Keywords:
Breast cancer; Neoadjuvant chemotherapy; Obesity; Race/ethnicity; Survival; Tumor subtype
Authors: Brionna Y Hair; Melissa A Troester; Sharon N Edmiston; Eloise A Parrish; Whitney R Robinson; Michael C Wu; Andrew F Olshan; Theresa Swift-Scanlan; Kathleen Conway Journal: Cancer Epidemiol Biomarkers Prev Date: 2015-01-12 Impact factor: 4.254
Authors: Sunil Verma; David Miles; Luca Gianni; Ian E Krop; Manfred Welslau; José Baselga; Mark Pegram; Do-Youn Oh; Véronique Diéras; Ellie Guardino; Liang Fang; Michael W Lu; Steven Olsen; Kim Blackwell Journal: N Engl J Med Date: 2012-10-01 Impact factor: 91.245
Authors: Wambui G Gathirua-Mwangi; Terrell W Zollinger; Mwangi J Murage; Kamnesh R Pradhan; Victoria L Champion Journal: Breast Cancer Date: 2015-09-08 Impact factor: 4.239
Authors: Stephen J Luen; Roberto Salgado; Stephen Fox; Peter Savas; Jennifer Eng-Wong; Emma Clark; Astrid Kiermaier; Sandra M Swain; Jose Baselga; Stefan Michiels; Sherene Loi Journal: Lancet Oncol Date: 2016-12-07 Impact factor: 41.316
Authors: Erica T Warner; Karla V Ballman; Carrie Strand; Judy C Boughey; Aman U Buzdar; Lisa A Carey; William M Sikov; Ann H Partridge Journal: Breast Cancer Res Treat Date: 2016-07-22 Impact factor: 4.872
Authors: Ivana Sestak; Wolfgang Distler; John F Forbes; Mitch Dowsett; Anthony Howell; Jack Cuzick Journal: J Clin Oncol Date: 2010-06-14 Impact factor: 44.544
Authors: V Sini; G Lunardi; M Cirillo; M Turazza; C Bighin; S Giraudi; A Levaggi; P Piccioli; G Bisagni; R Gnoni; G Stridi; M Porpiglia; E Picardo; R Ponzone; D Marenco; M Mansutti; F Puglisi; L Del Mastro Journal: Br J Cancer Date: 2014-01-21 Impact factor: 7.640
Authors: Peter Widschwendter; Thomas Wp Friedl; Lukas Schwentner; Nikolaus DeGregorio; Bernadette Jaeger; Amelie Schramm; Inga Bekes; Miriam Deniz; Krisztian Lato; Tobias Weissenbacher; Bernd Kost; Ulrich Andergassen; Julia Jueckstock; Julia Neugebauer; Elisabeth Trapp; Peter A Fasching; Matthias W Beckmann; Andreas Schneeweiss; Ines Schrader; Brigitte Rack; Wolfgang Janni; Christoph Scholz Journal: Breast Cancer Res Date: 2015-09-18 Impact factor: 6.466
Authors: Manuel U Ramirez; Kenysha Y J Clear; Zipporah Cornelius; Alaa Bawaneh; Yismeilin R Feliz-Mosquea; Adam S Wilson; Alistaire D Ruggiero; Nildris Cruz-Diaz; Lihong Shi; Bethany A Kerr; David R Soto-Pantoja; Katherine L Cook Journal: Physiol Rep Date: 2022-04
Authors: Emily A Teslow; Cristina Mitrea; Bin Bao; Ramzi M Mohammad; Lisa A Polin; Greg Dyson; Kristen S Purrington; Aliccia Bollig-Fischer Journal: Mol Oncol Date: 2019-03-01 Impact factor: 6.603